Concentra delivered a clean beat-and-raise third quarter. The occupational health provider earned $0.52 per share, beating the $0.45 consensus by 15.6% and growing earnings 33.3% year over year. Revenue rose 8.6% to $622.12 million, 3.7% above the $600.15 million consensus. GAAP and adjusted EPS were both $0.52, so the beat did not depend on add-backs. Management then raised full-year guidance for the third consecutive quarter. Adjusted EBITDA is now expected at $505 million to $510 million, up from $485 million to $495 million last quarter and $450 million to $470 million when the year began. The central development is not the beat itself but a shift in what is driving growth: patient volume is accelerating while pricing gains normalize.

The quality of the quarter holds up well. Revenue growth of 8.6% is slower than the 10.7% nine-month pace, but that reflects the 2025 acquisitions moving into the comparison base. Management said organic growth was slightly above the roughly 8% posted in Q2, so the underlying business did not slow. Operating leverage was strong. Cost of services rose only 5.2%, and income from operations climbed 21.9%. Adjusted EBITDA rose 17.9% to $140.2 million, and margin widened 178 basis points to 22.5%. Below the operating line, interest expense fell 12.3% as debt was paid down, and a slightly lower share count added a little more to EPS. One caveat is that G&A grew 15.2%, and adjusted G&A rose to 9.1% of revenue from 8.5%. That is a cost line worth watching as the company invests in its standalone infrastructure.

The operating story on the call was a volume re-acceleration. Total visits per day grew 4.9%, up from 2.6% in Q2. Employer services visits jumped 5.8%, versus just 1.8% the prior quarter. Management framed that as a leading indicator for workers' comp, where visits held at a steady 4.2%. Pricing moved the other way. Revenue per visit growth slowed to 3.3% from 4.6% in Q2, and workers' comp revenue per visit cooled to 3.5% from 4.9%. Management had guided toward roughly 3%, so this was expected rather than a surprise. Still, it means future growth leans more on volume and less on price. Onsite clinic growth also moderated to about 10% now that Pivot is in the organic base, compared with 27.9% organic growth in Q2.

Cash flow is where bears have legitimate ammunition. Third-quarter operating cash flow fell to $51.9 million from $60.6 million, and free cash flow dropped to $32.2 million from $40.2 million. Management cited working-capital timing and much higher cash taxes, which came to $31.6 million versus $3.6 million a year earlier. Nine-month free cash flow of $163.2 million is well ahead of last year's $99.3 million, so the dip looks like timing rather than deterioration. Even so, the company held full-year free cash flow guidance at $220 million to $240 million while raising its EBITDA outlook. The more important forward signal is that management said 2027 margin expansion will not match 2026's, with the aim mainly to sustain current margins. Workers' comp fee schedules for 2027 are also not yet known.

Capital allocation and balance-sheet progress added support. Concentra repaid $52.4 million of its term loan and bought back $34.7 million of stock. Net leverage now stands at 2.90x. S&P upgraded the company to BB, Moody's moved its outlook to positive, and the board authorized a new $250 million buyback. Growth levers remain active:

• 15 new centers in 2026, including a four-center Minnesota acquisition
• low double-digit de novo openings guided for 2027
• a possible New York entry following an E&M fee increase

The Select transition services agreement ends in November, which removes separation costs. The CEO and CFO handoff to Matt DiCanio and Tanner Newton is a change worth monitoring, though it was presented as continuity.

The market setup has changed sharply. Investor sentiment swung from slightly negative (-0.06) to strongly positive (+0.77), one of the larger shifts the scale allows. Shares have rallied 23.0% since the open after the August report, to $42.15, and sit 46.1% above the 200-day moving average. The fundamental story has been rewarded well before this print. Expectations are now considerably more demanding than they were a quarter ago.

The bottom line is that Concentra's quarter was high quality: a GAAP-backed beat, a third guidance raise, accelerating visit volume, and a strengthening balance sheet. The tension lies ahead. Pricing is normalizing toward 3%, 2027 margin expansion is expected to slow, and free cash flow guidance did not move. With sentiment and the stock price both stretched, continued volume strength may now be required just to sustain the rerating.